U.S. markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.8700-0.0900 (-4.59%)
At close: 04:00PM EST
1.8800 +0.01 (+0.53%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close1.9600
Bid1.8500 x 4000
Ask1.8900 x 2200
Day's Range1.8200 - 1.9800
52 Week Range1.4500 - 6.3200
Avg. Volume1,486,480
Market Cap310.186M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ATAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ATAI Life Sciences N.V.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Benzinga

    This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks

    HC Wainwright lowered the price target for Atai Life Sciences N.V. (NASDAQ: ATAI) from $50 to $20 to reflect recent adverse outcomes in programs such as PCN-101 in treatment-resistant depression and KUR-101 in opioid use disorder. Most recently, Atai Life Sciences-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants' depression rating scale score at 24 hours co

  • News Direct

    Trippy Trading: Top Psychedelic Stocks For 2023

    When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Leafly Holdings started the year with strong market performance. Innovative Industrial Properties’ market performance remained robust, following the announcement of significant dividends for 2022. Columbia Care subsidiary is carrying out large-scale cannabis industry layoffs. Key Takeaways; Psychedelic Sector Awakn’s ketamine-assisted psychotherapy for the treatment of AUD was ranked as the 5th […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector